Post-Market Clinical Follow-Up With the Patent Foramen Ovale Closure Device IrisFIT (Lifetech) in Patients With Stroke, Transient Ischemic Attack, or Other Thromboembolic Events

Kolja Sievert, Jiangtao Yu, Stefan Bertog, Marius Hornung, Ralph Stephan von Bardeleben, Sameer Gafoor, Markus Reinartz, Predrag Matic, Ilona Hofmann, Iris Grunwald, Nalan Schnelle, Horst Sievert (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

BACKGROUND: A patent foramen ovale (PFO) has been associated with embolic strokes and transient ischemic attacks (TIAs). Catheter closure of PFO is effective in preventing recurrent events. Residual shunts and procedure or device related complications can occur, including atrial fibrillation and thrombus formation. This study examines the initial experience with a new PFO closure device, the IrisFIT PFO-Occluder (Lifetech Scientific, Shenzhen, China).

METHODS: 95 patients with indications for PFO closure underwent percutaneous closure with the IrisFIT PFO-Occluder. The primary endpoint was the rate of accurate device placement with no/small residual shunt at 3 or 6 months follow-up. All patients underwent transoesophageal echocardiography (TEE) after 1 to 6 months. In case of a residual shunt, an additional TEE was performed after 12 months. Clinical follow-up was performed up to a mean of 33.1 ± 3.6 months.

RESULTS: The device was successfully implanted in 95 (100%) patients with no relevant procedural complications. At final TEE follow-up (7.6 ± 3.9 months) the effective closure rate was 96.8% with 1 moderate and 2 large residual shunts. There were 8 cases of new onset atrial fibrillation and 2 TIAs. There were no cases of device embolization or erosion.

CONCLUSION: The IrisFIT occluder is a new PFO closure device with several advantages compared to other devices. In this small study cohort, technical success rate, closure rate and adverse event rate were comparable to other devices. The rate of new onset atrial fibrillation was higher in comparison to other studies and warrants further investigation.

Original languageEnglish
Pages (from-to)72-75
Number of pages4
JournalCardiovascular revascularization medicine : including molecular interventions
Volume30
Early online date19 Aug 2021
DOIs
Publication statusPublished - Sept 2021

Keywords

  • Cardiac Catheterization/adverse effects
  • Follow-Up Studies
  • Foramen Ovale, Patent/complications
  • Humans
  • Ischemic Attack, Transient/etiology
  • Septal Occluder Device
  • Stroke/etiology
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Post-Market Clinical Follow-Up With the Patent Foramen Ovale Closure Device IrisFIT (Lifetech) in Patients With Stroke, Transient Ischemic Attack, or Other Thromboembolic Events'. Together they form a unique fingerprint.

Cite this